Profile data is unavailable for this security.
About the company
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.
- Revenue in HKD (TTM)1.74bn
- Net income in HKD-2.07bn
- Incorporated2012
- Employees2.53k
- LocationShanghai Junshi Biosciences Co Ltd16F, Building 7, No. 6, Lane 100Pingjiaqiao Road, Pudong New AreaSHANGHAI 201203ChinaCHN
- Phone+86 2 161058800
- Fax+86 2 161757377
- Websitehttps://www.junshipharma.com/
| Holder | Shares | % Held |
|---|---|---|
| GIC Pte Ltd. (Investment Management)as of 20 Feb 2024 | 15.34m | 7.00% |
| HHLR Advisors Ltd.as of 31 Dec 2023 | 11.40m | 5.20% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 6.43m | 2.93% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.10m | 0.96% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 2.08m | 0.95% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 797.00k | 0.36% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 791.00k | 0.36% |
| Value Partners Ltd.as of 30 Jun 2023 | 508.00k | 0.23% |
| HSBC Global Asset Management (UK) Ltd.as of 30 Aug 2024 | 430.32k | 0.20% |
| BlackRock Advisors (UK) Ltd.as of 07 Nov 2024 | 294.00k | 0.13% |
